Enzo Biochem, Inc.
https://www.enzo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Enzo Biochem, Inc.
Cancer, Gene Therapy Top US FDA’s Second Half 2024 User Fee Calendar
Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.
Eleven New Drugs Filed In EU; Sipavibart & Dorocubicel Win Fast-Track Status
AstraZeneca’s sipavibart for preventing COVID-19 in the highly vulnerable population of immunocompromised patients is among the latest drugs that the European Medicines Agency has started to review for potential pan-EU marketing authorization.
Orna Acquires ReNAgade, Bringing Their Shared RNA Interests Under One Roof
Orna emerged in 2021 with its circular RNA platform and ReNAgade launched in 2023 to deliver RNA to new tissues, both backed by MPM BioImpact, but they have been partners for years.
Radionuclide Therapy Developers Attract Investor Attention in March China Fundraising
China's Chengdu New Radiomedicine Technology and the radiotherapy CRDMO Mitro Biotech bagged a combined $94m in their respective new financing rounds during March. Meanwhile, Beijing Varnotech Biopharm secured $83m for its vaccine candidates for the prevention of herpes zoster and respiratory syncytial virus infections.
Company Information
- Industry
- Biotechnology
- Laboratory Testing Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Enzo Life Sciences
- Enzo Clinical Labs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice